Published in AJNR Am J Neuroradiol on March 18, 2010
Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging (2011) 1.40
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34
Improved DTI registration allows voxel-based analysis that outperforms tract-based spatial statistics. Neuroimage (2014) 1.19
Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology (2014) 1.07
Concurrent hippocampal induction of MHC II pathway components and glial activation with advanced aging is not correlated with cognitive impairment. J Neuroinflammation (2011) 1.05
18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging (2014) 0.92
Focal hemosiderin deposits and β-amyloid load in the ADNI cohort. Alzheimers Dement (2013) 0.91
Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging (2014) 0.89
The hippocampal neuroproteome with aging and cognitive decline: past progress and future directions. Front Aging Neurosci (2011) 0.86
Cortical hypermetabolism in MCI subjects: a compensatory mechanism? Eur J Nucl Med Mol Imaging (2014) 0.83
Effect of intellectual enrichment on AD biomarker trajectories: Longitudinal imaging study. Neurology (2016) 0.82
p53-dependent SIRT6 expression protects Aβ42-induced DNA damage. Sci Rep (2016) 0.80
Alzheimer's disease: Unique markers for diagnosis & new treatment modalities. Indian J Med Res (2015) 0.77
Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using (18)F-FDG-PET. Int J Mol Sci (2016) 0.77
Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: comparison of two prospective cohort studies. BMJ Open (2012) 0.76
MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease. J Neuroimaging (2014) 0.76
Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Neurodegener Dis Manag (2015) 0.75
Alzheimer's disease - not an exaggeration of healthy aging. Indian J Psychol Med (2011) 0.75
Olfactory Identification Deficits, Cognitive Decline, and Dementia in Older Adults. Am J Geriatr Psychiatry (2016) 0.75
Effects of metformin on the cerebral metabolic changes in type 2 diabetic patients. ScientificWorldJournal (2014) 0.75
Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology (2016) 0.75
Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage (2002) 49.90
Unified segmentation. Neuroimage (2005) 30.20
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
Natural history of mild cognitive impairment in older persons. Neurology (2002) 6.09
The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology (2006) 3.69
Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology (2003) 3.60
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci (2001) 3.35
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Mayo Clinic Alzheimer's Disease Patient Registry. Aging (Milano) (1990) 2.77
FDG PET imaging in patients with pathologically verified dementia. J Nucl Med (2000) 2.70
Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med (1999) 2.30
Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol (2003) 2.26
Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage (2008) 1.98
What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology (2007) 1.95
Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol (2005) 1.82
Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain (2005) 1.60
Early detection of Alzheimer's disease using neuroimaging. Exp Gerontol (2006) 1.41
Automated template-based PET region of interest analyses in the aging brain. Neuroimage (2006) 1.22
Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol (2008) 1.22
Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol (2002) 0.98
Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci (2002) 0.98
Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med (2007) 0.90
Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J Neuroimaging (2009) 0.86
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Classification of primary progressive aphasia and its variants. Neurology (2011) 11.82
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA (1994) 5.98
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology (2004) 4.74
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology (2008) 4.31
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology (2000) 3.84
Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology (2010) 3.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Cognitive impairment in hemodialysis patients is common. Neurology (2006) 3.68
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol (1991) 3.45
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology (2011) 3.30
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology (2007) 3.24
Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study. Neurology (2005) 3.21
Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology (1989) 3.12
The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology (2012) 3.01
Intracerebral hemorrhage after fibrinolytic therapy for acute myocardial infarction. Stroke (1993) 2.98
Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology (2007) 2.93
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 2.88
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain (2000) 2.76
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Memory and MRI-based hippocampal volumes in aging and AD. Neurology (2000) 2.65
REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology (2010) 2.50
Reporting potential bias: Neurology's evolving policies. Neurology (2011) 2.46
Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology (2008) 2.45